Study guide

4.3 Patient Profile Requirements & Retrospective DUR

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

4.3 Patient Profile Requirements & Retrospective DUR

Key Takeaways Explain This Topic AI

OBRA '90 mandates that pharmacists make a reasonable effort to collect, maintain, and update individual patient profile records for all ambulatory patients.

Mandatory patient profile data includes demographic information, disease states, known allergies/drug reactions, a complete medication history (including OTCs/herbals), and pharmacist comments.

Patient profile records and prescription logs must be retained for a minimum of 2 years under federal baseline standards (with many states requiring up to 5 or 10 years).

Retrospective Drug Utilization Review (RetroDUR) evaluates historical claims data post-dispensing across patient populations to detect fraud, waste, abuse, and inappropriate prescribing patterns.

State DUR Boards, comprising physicians and pharmacists, review RetroDUR data to establish clinical guidelines and execute prescriber/pharmacist educational interventions.

Last updated: July 2026

4.3 Patient Profile Requirements & Retrospective DUR

The third fundamental pillar of the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) encompasses the statutory mandates for patient profile maintenance and Retrospective Drug Utilization Review (RetroDUR) . Together, these requirements create a comprehensive longitudinal record of patient care and establish a macro-level quality assurance mechanism across state healthcare systems.

Patient Profile Requirements Under OBRA '90

OBRA '90 mandates that a pharmacy must make a reasonable effort to collect, record, and maintain detailed patient profile records for all ambulatory patients receiving prescription therapy. The patient profile serves as the clinical foundation for all Prospective Drug Utilization Reviews (ProDUR) and counseling evaluations.

Mandatory Data Elements of a Patient Profile

Under OBRA '90 regulations (42 CFR § 456.705) and state pharmacy board rules, the pharmacist or pharmacy staff must attempt to collect and document the following core categories of information:

  • 1. Demographic & Contact Data
  • Full legal name of the patient
  • Primary residential address and telephone number
  • Date of birth (or age) and gender
  • 2. Individual Clinical & Medication History

Chronic Disease States: Significant medical conditions, chronic illnesses, or physical impairment records (e.g., diabetes, hypertension, end-stage renal disease).

Known Allergies & Drug Reactions: Documented drug allergies, specific immunological reaction types (e.g., anaphylaxis, rash, angioedema), and history of severe adverse drug reactions.

Comprehensive Medication List: A complete listing of all prescription medications, over-the-counter (OTC) drugs, herbal remedies, and dietary supplements routinely used by the patient, along with relevant medical devices.

3. Pharmacist Comments & Clinical Observations

Pharmacist clinical notes regarding drug therapy management.

Documentation of prior DUR warnings and their clinical resolutions.

Patient preferences, special communication needs, or documented counseling refusals.

Record Retention Requirements

A critical subject tested on the MPJE is the statutory timeline for preserving pharmacy records, including patient profiles, prescription order logs, and DUR documentation.

Federal Baseline Standard: Under federal OBRA '90 regulations and the federal Controlled Substances Act (CSA), prescription records and patient profiles must be retained for a minimum of two (2) years from the date of the last entry or dispensing transaction.

State Law Variations: Many state boards of pharmacy enforce longer retention periods—such as 5, 6, 7, or even 10 years—for patient profiles and prescription records. For the MPJE, candidates must remember that where federal and state laws conflict, the pharmacist must follow the more stringent standard .

Retrospective Drug Utilization Review (RetroDUR)

While Prospective DUR occurs at the point of sale prior to dispensing, Retrospective Drug Utilization Review (RetroDUR) is conducted after medications have been dispensed and consumed by patients.

Mechanics and Data Sources of RetroDUR

RetroDUR relies on big data analytics and electronic claims processing databases. It is primarily executed by:

  • State Medicaid Agencies
  • Health Maintenance Organizations (HMOs) and Managed Care Organizations (MCOs)
  • Pharmacy Benefit Managers (PBMs)

Computers scan millions of paid prescription claims, medical diagnostic codes (ICD-10), and hospital discharge summaries across defined patient populations over rolling periods (e.g., monthly, quarterly, or annually).

Objectives of Retrospective DUR

Unlike Prospective DUR, which protects individual patients in real-time, RetroDUR operates at a population health and systems level . The primary objectives of RetroDUR include:

Identifying Systemic Prescribing & Dispensing Patterns: Detecting widespread off-guideline prescribing, inappropriate polypharmacy in elderly populations, or chronic under-dosing of essential disease-modifying drugs.

Detecting Fraud, Waste, and Abuse: Identifying "pill mill" prescribers, fraudulent billing practices, excessive early refills across multiple pharmacies, or patient doctor-shopping schemes.

Evaluating Therapeutic Duplication Across Multiple Providers: Discovering instances where patients receive duplicate therapies prescribed by different specialists who fail to coordinate care.

Assessing Clinical Outcomes & Cost Efficacy: Measuring whether state Medicaid drug therapy guidelines correlate with reduced emergency room visits and hospital readmissions.

The Role of the Drug Utilization Review (DUR) Board

OBRA '90 mandated that every state establishing a Medicaid DUR program must appoint an official Drug Utilization Review (DUR) Board .

Composition of the DUR Board

By federal law, the state DUR Board must comprise an equal or balanced representation of healthcare professionals, specifically including:

  • Licensed practicing physicians
  • Licensed practicing pharmacists
  • Core Functions & Educational Interventions

The DUR Board reviews the analytical data generated by RetroDUR screening algorithms and formulates policy recommendations. Crucially, the DUR Board does not act primarily as a punitive body; rather, its mandate is educational .

Key DUR Board interventions include:

Academic Detailing & Provider Education: Sending clinical educational letters to prescribers or pharmacists whose prescribing or dispensing patterns deviate significantly from established clinical practice guidelines.

Formulary & Prior Authorization Criteria: Establishing evidence-based preferred drug lists (PDLs) and prior authorization criteria for state Medicaid programs.

Continuing Education Programs: Developing mandatory continuing education modules for pharmacists and prescribers targeting identified areas of medication misuse or safety concerns.

Summary Table: Mandatory vs. Optional Patient Profile Elements

  • Profile Category OBRA '90 Mandatory Elements Optional / Best Practice Elements
  • Demographics Full name, address, phone #, DOB/age, gender Emergency contact, primary language spoken

Clinical History Chronic disease states, documented allergies, drug reactions Height, weight, serum creatinine / CrCl

Medication List All current prescriptions, OTCs, herbals, devices Preferred pharmacy location, mail preference

Pharmacy Notes Pharmacist clinical comments, DUR resolutions, refusals Patient insurance copay tier preferences

Summary Table: Prospective DUR vs. Retrospective DUR Comparison

  • Operational Aspect Prospective DUR (ProDUR) Retrospective DUR (RetroDUR)
  • Primary Execution Time Prior to dispensing (Point of Sale) Months/quarters post-dispensing
  • Data Level Analyzed Single prescription & individual profile Millions of aggregated electronic claims
  • Primary Executor Dispensing Community Pharmacist State DUR Board, Medicaid Agency, PBM
  • Primary Goal Prevent immediate individual harm Improve population outcomes, reduce fraud

Target Interventions Contact prescriber, cancel fill, counsel patient Academic detailing letters, policy edits, CE

Loading diagram... Retrospective Drug Utilization Review (RetroDUR) Feedback Loop